Lee DH, et al. - In this study involving Korean diabetic patients with subclinical coronary atherosclerosis, researchers assessed the impact of cilostazol vs aspirin. For this prospective study, 100 patients with diabetes and mild-to-moderate coronary atherosclerosis were randomized to groups of either 200-mg/day cilostazol (CTZ) or 100-mg/day aspirin (n=50 each). Investigators found that treatment with CTZ for 12 months reduced stenosis of the coronary artery and noncalcified plaque. In the CTZ group, they observed an increase in HDL-cholesterol levels; a decrease in triglyceride, liver enzyme, and hsCRP levels; and a reduction in abdominal visceral fat area and insulin resistance. In patients with diabetes, CTZ treatment could be an option for preventing the progression of coronary atherosclerosis.